Table 4. Factors related to PFS.
| Factors | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Smoking index | 1.000 (0.999–1.001) | 0.685 | |||
| ECOG PS | 0.950 (0.400–2.258) | 0.908 | |||
| Histology | |||||
| Adenocarcinoma | 1 | 0.843 | |||
| Squamous cell carcinoma | 1.292 (0.285–5.860) | 0.740 | |||
| Other | 1.514 (0.333–6.886) | 0.591 | |||
| TNM stage | 1.042 (0.409–2.651) | 0.931 | |||
| Anti-COPD drugs | 1.187 (0.352–4.004) | 0.783 | |||
| GOLD degree | 1.667 (1.038–2.677) | 0.034 | |||
| Cytokines | |||||
| IL-6 | 1.001 (1.000–1.002) | 0.003 | 1.001 (1.000–1.002) | 0.007 | |
| IL-8 | 1.014 (1.004–1.024) | 0.005 | |||
| IL-10 | 1.049 (1.010–1.090) | 0.014 | |||
| KL-6 | 1.000 (0.999–1.001) | 0.833 | |||
PFS, progression-free survival; ECOG, Eastern Cooperative Oncology Group; PS, physical state; TNM, tumor node metastasis; COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; IL-6, interleukin-6; IL-8, interleukin-8; IL-10, interleukin-10; KL-6, Krebs Von den Lungen-6; HR, hazard ratio; CI, confidence interval.